Olaparib

Generic Name
Olaparib
Brand Names
Lynparza
Drug Type
Small Molecule
Chemical Formula
C24H23FN4O3
CAS Number
763113-22-0
Unique Ingredient Identifier
WOH1JD9AR8
Background

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...

Indication

Ovarian cancer

Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions
Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients

First Posted Date
2016-04-29
Last Posted Date
2021-12-07
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
35
Registration Number
NCT02755844
Locations
🇫🇷

Centre Hospitalier Lyon Sud, Pierre Benite, France

🇫🇷

Comité Gynécologique, Institut Gustave Roussy, Villejuif, France

🇫🇷

Département d'Oncologie Médicale, Centre Antoine Lacassagne, Nice, France

and more 3 locations

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

Phase 1
Active, not recruiting
Conditions
Breast
SCLC
Gastric Cancers
Ovarian
Interventions
Drug: Olaparib
Drug: MEDI4736
Drug: Bevacizumab
First Posted Date
2016-04-12
Last Posted Date
2024-12-02
Lead Sponsor
AstraZeneca
Target Recruit Count
264
Registration Number
NCT02734004
Locations
🇬🇧

Research Site, Sutton, United Kingdom

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

First Posted Date
2016-02-26
Last Posted Date
2024-11-11
Lead Sponsor
American Society of Clinical Oncology
Target Recruit Count
3791
Registration Number
NCT02693535
Locations
🇺🇸

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

🇺🇸

Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States

🇺🇸

Sutter Auburn, Auburn, California, United States

and more 125 locations

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Phase 1
Withdrawn
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Drug: Olaparib
First Posted Date
2016-02-19
Last Posted Date
2020-01-13
Lead Sponsor
Yale University
Registration Number
NCT02686008

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

Not Applicable
Completed
Conditions
Ovarian Cancer
Interventions
Drug: Cediranib
Drug: Olaparib
First Posted Date
2016-02-12
Last Posted Date
2022-05-09
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
34
Registration Number
NCT02681237
Locations
🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

First Posted Date
2016-02-12
Last Posted Date
2016-02-15
Lead Sponsor
Istituti Ospitalieri di Cremona
Target Recruit Count
45
Registration Number
NCT02681562

Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer

First Posted Date
2016-02-11
Last Posted Date
2017-08-01
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
600
Registration Number
NCT02679963
Locations
🇫🇷

Gustave Roussy Cancer Campus, Villejuif, Val de Marne, France

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

First Posted Date
2016-02-09
Last Posted Date
2024-10-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
24
Registration Number
NCT02677038
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

First Posted Date
2015-10-27
Last Posted Date
2022-09-19
Lead Sponsor
AstraZeneca
Target Recruit Count
84
Registration Number
NCT02588105
Locations
🇬🇧

Research Site, Manchester, United Kingdom

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

First Posted Date
2015-10-08
Last Posted Date
2024-01-11
Lead Sponsor
New Mexico Cancer Care Alliance
Target Recruit Count
50
Registration Number
NCT02571725
Locations
🇺🇸

University of Virginia Cancer Center, Charlottesville, Virginia, United States

🇺🇸

Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States

🇺🇸

University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy